EMA Authorised: Xenleta (lefamulin acetate) — Nabriva Therapeutics Ireland DAC

View source ↗

Summary

The European Medicines Agency authorised Xenleta (lefamulin acetate) for treatment of community-acquired pneumonia, expanding options for bacterial pneumonia in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia

Drugs mentioned

• Xenleta (lefamulin)

Snippet

Status: Authorised. Therapeutic area: Pneumonia, Bacterial;Community-Acquired Infections. MAH: Nabriva Therapeutics Ireland DAC. Decision date: 04/04/2025